BerandaIMMP • NASDAQ
add
Immutep Ltd - ADR
$2,94
Setelah Jam Perdagangan Normal:(1,70%)+0,050
$2,99
Tutup: 16 Jan, 18.51.50 GMT-5 · USD · NASDAQ · Pernyataan Penyangkalan
Tutup sebelumnya
$3,03
Rentang hari
$2,90 - $3,06
Rentang tahun
$1,32 - $3,53
Kapitalisasi pasar
434,62Â jt USD
Volume Rata-Rata
1,33Â jt
Rasio P/E
-
Hasil dividen
-
Dalam berita
Keuangan
Laporan Laba Rugi
Pendapatan
Penghasilan bersih
| (AUD) | Jun 2025info | Perubahan Y/Y |
|---|---|---|
Pendapatan | 948,05Â rb | 9,53% |
Biaya operasional | 2,21Â jt | 8,90% |
Penghasilan bersih | -19,53Â jt | -81,76% |
Margin laba bersih | -2,06Â rb | -65,94% |
Penghasilan per saham | — | — |
EBITDA | -18,24Â jt | -62,71% |
Tarif pajak efektif | — | — |
Neraca
Total aset
Total liabilitas
| (AUD) | Jun 2025info | Perubahan Y/Y |
|---|---|---|
Investasi tunai jangka pdk | 129,69Â jt | -28,69% |
Total aset | 156,98Â jt | -22,12% |
Total liabilitas | 13,35Â jt | 10,70% |
Total ekuitas | 143,64 jt | — |
Saham yang beredar | 1,47 M | — |
Harga terhadap nilai buku | 30,30 | — |
Tingkat pengembalian aset | -30,73% | — |
Tingkat pengembalian modal | -33,21% | — |
Arus Kas
Perubahan kas bersih
| (AUD) | Jun 2025info | Perubahan Y/Y |
|---|---|---|
Penghasilan bersih | -19,53Â jt | -81,76% |
Kas dari operasi | -16,75Â jt | -104,65% |
Kas dari investasi | 12,14Â jt | 217,88% |
Kas dari pembiayaan | -48,98Â rb | -100,10% |
Perubahan kas bersih | -3,24Â jt | -111,16% |
Arus kas bebas | -10,32Â jt | -84,32% |
Tentang
Immutep Ltd is a biotechnology company working primarily in the field of cancer immunotherapy using the LAG3 immune control mechanism. The company was originally built on CVac, a therapeutic cancer vaccine. In late 2014 the privately held French immunotherapy company Immutep SA was purchased by Prima Biotech.
Prima currently has three main products in its pipeline, all acquired with Immutep:
Eftilagimod alpha, which is recombinant soluble LAG-3, used as an activator of antigen presenting cells. This product has completed a Phase IIa clinical study, where it doubled the expected response rate in HER2-negative metastatic breast cancer.
IMP731, a depleting monoclonal antibody for autoimmune diseases, targeting LAG-3+ activated T cells. This antibody has been licensed to GlaxoSmithKline.
IMP701, an antagonist monoclonal antibody to LAG3 for use in cancer. This product has been licensed to Novartis. Wikipedia
CEO
Didirikan
2001
Situs
Karyawan
19
